Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 205-598-9 | CAS number: 143-29-3
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Endpoint summary
Administrative data
Description of key information
oral
rat: LD50 > 2000 mg/kg bw (GLP, OECD 425; Langobardi 2003)
dermal
rat: L50 > 2000 mg/kg bw (GLP, OECD 402; Langobardi 2004)
inhalation
no reliable data availabe
Key value for chemical safety assessment
Acute toxicity: via oral route
Endpoint conclusion
- Dose descriptor:
- LD50
- Value:
- 2 000 mg/kg bw
Acute toxicity: via dermal route
Endpoint conclusion
- Dose descriptor:
- LD50
- Value:
- 2 000 mg/kg bw
Additional information
There are reliable data available to assess the acute toxicity of the substance after oral, dermal and inhalative application.
Oral
In a GLP compliant study performed according to OECD test guideline 425 (Longobardi, 2003), 5 female Sprague-Dawley rats received 2000 mg/kg bw of hexaoxatricosane by gavage and were subsequently observed for 14 days. At the end of the observation period, all survivors were sacrificed and submitted to gross-pathological examination. One animal died at 2000 mg/kg bw within approximately one hour of dosing, therefore the LD50 level was > 2000 mg/kg bw. The clinical signs observed at 2000 mg/kg bw comprised convulsions, lacrimation, salivation, lethargy, piloerection, reduced activity on day 1 and hunched posture on days 2 and 3. No abnormalities were observed in any animal at the necropsy examination performed at the end of the observation period or in the early decedent animal.
In a supporting study the acute oral toxicity of hexaoxatricosane in Sherman Wistar rats was determined to be approximately 3310 mg/kg (Shelanski, 1958)
Dermal
There are two studies available adressing the acute dermal toxicity of hexaoxatricosane in two different species. In a GLP compliant study according to OECD test guideline 402 male and female Spraque-Dawley rats (10/sex/dose) received a single dermal dose of 2000 mg/kg bw over 24 hours (Longobardi, 2004). After removal of the test substance the test animals were observed for 14 days. No mortality occured. Apart from reduced body weight gain in the female group at the end of the observation period no clinical signs of toxicity and no pathological abnormalities were observed.
The findings in the key study are supported by a second acute dermal toxicity study in rabbits (Green, 1977). Six male and six female rabbits were topically exposed to 2000 mg/kg bw of the test substance for 24 h. No mortalities and no signs of toxicity were observed.
Inhalation
Limited information is available on the acute inhalation toxictiy of hexaoxatricosane (Green, 1977). For both, vapor and aerosol an inhalation hazard test with whole body exposure for 1 hour was performed in rats and mice. A very high aerosolic concentration of 200 mg/l was reported. This value is not comprehensible and therefore, the reference is considered as not reliable (Klimisch code 3).
No human information is available on the acute toxicity (oral, dermal and inhalation) of hexaoxatricosane.
Justification for classification or non-classification
Based on the available data on the acute toxicity of hexaoxatricosane no classification is warranted according to the criteria of both, 67/548/EEC and CLP regulation (EC) 1272/2008.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
